Table 3 Univariate and multivariate analysis for OS

Age (≤ 49 vs. > 49) ^a

1.63 (1.09–2.45)

0.019

Position (left vs. right)

1.05 (0.7–1.57)

0.830

BMI (< 24 vs. ≥ 24)

1.26 (0.84–1.88)

0.269

Height (≤ 1.6 vs. > 1.6)

0.8 (0.53–1.2)

0.277

Weight (≤ 61.5 vs. > 61.5)

1.13 (0.76–1.69)

0.551

Menopause (no vs. yes) ^a

1.74 (1.16–2.6)

0.008

Preneoadjuvant chemotherapy hematological parameters

 mSIS (high risk vs. low risk)

0.53 (0.34–0.82)

0.004

0.60 (0.38–0.96)

0.0322

 SIS (high risk vs. low risk)

1.17 (0.74–1.85)

0.513

 NLR (≤ 2.24 vs. > 2.24) ^a

1.88 (1.25–2.83)

0.002

 LMR (≤ 2.96 vs. > 2.96)

0.55 (0.32–0.94)

0.028

0.70 (0.39–1.24)

0.2216

 Lymphocyte (≤ 1.96 vs. > 1.96)

0.88 (0.59–1.32)

0.532

 Neutrophil (≤ 3.76 vs. > 3.76)

1.12 (0.75–1.67)

0.591

 Monocyte (≤ 0.41 vs. > 0.41)

0.85 (0.57–1.28)

0.437

 Hemoglobin (≤ 135.4 vs. > 135.4)

0.65 (0.43–0.98)

0.041

0.76 (0.50–1.16)

0.2085

 Platelet (≤ 242 vs. > 242)

0.99 (0.66–1.47)

0.944

 Albumin (≤ 46.3 vs. > 46.3)

1.27 (0.82–1.97)

0.279

 Globulin (≤ 30 vs. > 30)

1.03 (0.69–1.53)

0.900

 Clinical T stage (1 vs. 2)

1.1 (0.56–2.15)

0.776

0.90 (0.46–1.78)

0.7663

 Clinical T stage (1 vs. 3)

1.38 (0.64–2.96)

0.414

1.05 (0.48–2.28)

0.9050

 Clinical T stage (1 vs. 4)

4.51 (1.41–14.41)

0.011

3.43 (1.05–11.2)

0.0410

 Clinical N stage (0 vs. 1)

2.08 (0.59–7.39)

0.255

 Clinical N stage (0 vs. 2)

1.37 (0.43–4.38)

0.595

 Clinical N stage (0 vs. 3)

1.72 (0.52–5.68)

0.375

 Clinical TNM stage (I + II vs. III)

0.82 (0.46–1.44)

0.486

 Subtype (luminal A vs. B)

1.84 (0.87–3.89)

0.110

 Subtype (luminal A vs. HER-2 OE)

1.15 (0.49–2.66)

0.752

 Subtype (luminal A vs. TNBC)

1.91 (0.85–4.32)

0.119

 ER (negative vs. positive)

1.16 (0.77–1.74)

0.482

 PR (negative vs. positive)

1.05 (0.7–1.57)

0.812

 HER-2 (negative vs. low expression)

0.94 (0.58–1.53)

0.798

 HER-2 (negative vs. positive)

0.74 (0.46–1.21)

0.232

 Ki-67 (≤ 14% vs. > 14%)

1.23 (0.79–1.89)

0.358

 P53 (negative vs. positive)

1.17 (0.76–1.81)

0.466

Post neoadjuvant chemotherapy hematological parameters

 Lymphocyte (≤ 1.54 vs. > 1.54)

1.02 (0.68–1.53)

0.914

 Neutrophil (≤ 3.75 vs. > 3.75)

1.06 (0.71–1.58)

0.793

 Monocyte (≤ 0.53 vs. > 0.53)

0.79 (0.53–1.19)

0.255

 Hemoglobin (≤ 117 vs. > 117)

0.75 (0.5–1.13)

0.172

 Platelet (≤ 271 vs. > 271)

1.24 (0.83–1.86)

0.296

 Albumin (≤ 46.3 vs. > 46.3)

1.03 (0.6–1.76)

0.922

 Globulin (≤ 28 vs. > 28)

0.92 (0.61–1.38)

0.688

 Cycle (< 4 vs. ≥ 4)

0.74 (0.43–1.26)

0.264

 pCR (no vs. yes)

0.41 (0.21–0.82)

0.012

0.40 (0.20–0.80)

0.0096